

The information in the press release is intended for investors.

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2024

GOTHENBURG, Sweden, April 11, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2024 are now available, in Swedish as well as an English translation, on the company's website, www.isofolmedical.com.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, Chief Executive Officer

E-mail: petter.s.lindqvist@isofolmedical.com

Phone: +46 (0) 739 60 12 56

Margareta Hagman, Chief Financial Officer

E-mail: margareta.hagman@isofolmedical.com

Phone: +46 (0) 738 73 34 18

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on April 11, 2025.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com